The worldwide prevalence of both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) has rapidly increased over the past 30 years 1,2 , with consequential increases in the prevalence of microvascular and macrovascular diabetes complications [3] [4] [5] [6] [7] . Epidemiological studies show that improvements in diabetes management have led to reductions in diabetes-associated cardiovascular morbidity over recent decades; however, the impact of these strategies on rates of end-stage renal disease (ESRD) have been minimal 8 . Approximately 30-40% of patients with T1DM and T2DM develop DKD, and about 50% of them can progress to ESRD [9] [10] [11] [12] . Current therapies to manage DKD include control of blood pressure and glucose levels and treatment with angiotensin-receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors; however, these modalities show limited efficacy in preventing the progression of DKD. Genetic factors and signal transduction pathways affect the expression of genes and phenotypes associated with DKD. However, the escalating rates of DKD indicate the need for a more in-depth understanding of the underlying molecular mechanisms to identify better therapies for this disease [13] [14] [15] [16] . Epigenetic mechanisms can affect gene expression and function without changing the underlying DNA sequence and can mediate crosstalk between genes and the environment 17, 18 . As the development and progression of diabetes mellitus and DKD are strongly influenced by environmental factors, such as nutritional status, which in turn alters epigenetic states, it is likely that epigenetic mechanisms have a key role in the pathogenesis of DKD 14, 19, 20 . In this Review, we describe our current understanding of the role of epigenetics and epigenomics in DKD. We discuss how epigenetic factors and non-coding RNAs (ncRNAs) could be used as biomarkers and drug targets for DKD diagnosis, prognosis and treatment, and we highlight how our rapidly expanding knowledge of epigenetic variations opens a window of opportunity for improved clinical management of DKD.
. Approximately 30-40% of patients with T1DM and T2DM develop DKD, and about 50% of them can progress to ESRD [9] [10] [11] [12] . Current therapies to manage DKD include control of blood pressure and glucose levels and treatment with angiotensin-receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors; however, these modalities show limited efficacy in preventing the progression of DKD. Genetic factors and signal transduction pathways affect the expression of genes and phenotypes associated with DKD. However, the escalating rates of DKD indicate the need for a more in-depth understanding of the underlying molecular mechanisms to identify better therapies for this disease [13] [14] [15] [16] . Epigenetic mechanisms can affect gene expression and function without changing the underlying DNA sequence and can mediate crosstalk between genes and the environment 17, 18 . As the development and progression of diabetes mellitus and DKD are strongly influenced by environmental factors, such as nutritional status, which in turn alters epigenetic states, it is likely that epigenetic mechanisms have a key role in the pathogenesis of DKD 14, 19, 20 . In this Review, we describe our current understanding of the role of epigenetics and epigenomics in DKD. We discuss how epigenetic factors and non-coding RNAs (ncRNAs) could be used as biomarkers and drug targets for DKD diagnosis, prognosis and treatment, and we highlight how our rapidly expanding knowledge of epigenetic variations opens a window of opportunity for improved clinical management of DKD.
Pathogenesis of DKD
DKD is characterized by an accumulation of extracellular matrix (ECM) proteins such as collagen and fibronectin in renal compartments, resulting in tubular interstitial fibrosis, glomerular mesangial hypertrophy and expansion, thickening of the glomerular basement membrane, podocyte foot process effacement and inflammation due to the infiltration of monocytes and macrophages. All of these factors contribute to renal dysfunction and can ultimately lead to ESRD 13, [21] [22] [23] . Diabetogenic stimuli, including high blood glucose levels (>15 mM); advanced glycation end products (AGEs); growth factors such as transforming growth factor-β1 (TGFβ1), angiotensin II (AngII) and platelet-derived growth factor; and inflammatory cytokines, have been implicated in the pathogenesis of DKD owing to their adverse effects on multiple renal cell types [24] [25] [26] [27] [28] [29] . Upregulation of the above-mentioned growth factors and cytokines activates signal transduction pathways, including protein kinase C and AKT kinase cascades, leading to the activation of key effector transcription factors such as SMADs, nuclear factor-κB (NF-κB) and upstream stimulatory factors (USFs) (Fig. 1) . Together, these mechanisms promote the expression of genes associated with fibrosis, hypertrophy, apoptosis, inflammation, oxidative stress, endoplasmic reticulum (ER) stress, mitochondrial dysfunction and autophagy [13] [14] [15] [16] 22, [28] [29] [30] [31] [32] [33] [34] [35] [36] (Fig. 1 ). In particular, TGFβ1, which is overexpressed in several renal cell types in diabetes mellitus, has been widely studied in DKD progression owing to its pro-fibrotic effects 13, 21, 26, 27 . Identification of these pathways and the use of unbiased transcriptomic profiling approaches to uncover additional pathogenic factors have led to the initiation of clinical trials to assess new therapeutic targets in DKD [37] [38] [39] [40] [41] [42] . However, the escalating rates of DKD underscore the need to explore the contribution of other mechanisms, such as epigenetics, to DKD, particularly for patients with long-standing diabetes mellitus who experience persistent complications even after glucose normalization, a phenomenon attributed to metabolic (or hyperglycaemic) memory.
Metabolic memory in DKD
Most complications in patients with diabetes mellitus are associated with hyperglycaemia. Although glucose levels can be controlled through diet, exercise and medications including insulin, many patients continue to experience numerous life-threatening complications following glucose normalization, suggesting the existence of a 'memory' of the prior glucose exposure in target cells, which leads to persistence of its detrimental effects long after glycaemic control has been established [43] [44] [45] [46] . The phenomenon of hyperglycaemic memory has been observed in clinical trials and experimental models. The landmark Diabetes Control and Complications Trial (DCCT) showed that intensive glycaemic control delayed progression of microvascular complications, including nephropathy and neuropathy, compared with conventional therapy in patients with T1DM. After cessation of the DCCT in 1993, both groups of patients received intensive glycaemic control and were monitored long term (1994 to present) as part of the observational Epidemiology of Diabetes Intervention and Complications (EDIC) study 47 . During EDIC, both groups achieved similar mean haemoglobin A 1c (HbA 1c ) levels of approximately 8% 43, 44 . However, patients in the original DCCT intensive treatment group demonstrated a significantly lower risk of developing microvascular and macrovascular complications relative to those of patients in the original conventional treatment arm of DCCT [43] [44] [45] [46] . This difference in risk between the two groups was attributed to prolonged hyperglycaemia in the conventional therapy group during DCCT. The UK Prospective Diabetes Study reported similar long-term benefits of intensive glycaemic control in patients with T2DM. These benefits lasted well after cessation of the intervention, suggesting a 'legacy effect' of glycaemic control 48 . The persistent effects of high glucose through metabolic memory remain a major hurdle in the effective management of diabetic complications. An increasing body of evidence supports a role for epigenetic mechanisms in metabolic memory, suggesting that targeting these mechanisms might offer opportunities for the development of novel approaches to prevent and treat persistent diabetic complications, including DKD.
Epigenetics: new insights into DKD genome-wide association studies (GWAS) have identified only a few potential genes, loci and single-nucleotide polymorphisms (SNPs) associated with DKD, and few of these have achieved genome-wide significance in replication studies [49] [50] [51] [52] . By contrast, a growing body of literature implicates a role for epigenetic modifications in DKD, particularly because they can induce changes in the expression of genes in response to environmental factors 14, [53] [54] [55] [56] . Epigenetic modifications enable mitotically and/or meiotically heritable changes in gene function to occur without altering the underlying DNA sequence 17, 18 . Of note, most disease-associated SNPs are present in non-coding regions of the genome, including regulatory regions such as promoters and enhancers, and in ncRNAs 57 , which can affect gene expression by altering transcription factor binding and chromatin accessibility and through other epigenetic mechanisms. Thus,
Key points
• Diabetic kidney disease (DKD), involving the accumulation of extracellular matrix, hypertrophy and fibrosis in kidney glomerular and tubular cells, can lead to end-stage renal disease.
• Genes associated with DKD are regulated not only by classical signalling pathways and transcription factors but also by epigenetic mechanisms, including chromatin histone modifications, DNA methylation and non-coding RNAs.
• metabolic memory is a phenomenon characterized by the persistent expression of DKD-related genes and phenotypes induced by glycaemic exposure despite subsequent glycaemic control.
• Persistent epigenetic changes (DNA methylation and histone modifications) and signalling circuitry mediated by non-coding RNAs may be involved in metabolic memory.
• Targeting epigenetic factors (using small molecules or locus-specific epigenetic editing via the CRISPR-Cas9 system) or non-coding RNAs (using chemically modified antisense oligonucleotides) are potential approaches to prevent or treat DKD and erase metabolic memory.
• epigenetic profiling through epigenome-wide association studies and RNA (transcriptome) profiling of patient samples (blood, urine and biopsy samples) might facilitate a precision (personalized) medicine approach for the treatment of DKD.
findings from GWAS and epigenome studies show convergence on shared pathways, suggesting that combined analyses of genetic and epigenetic susceptibility loci might provide a powerful approach to identify pathogenic pathways in DKD, as has been done in chronic kidney disease (CKD) 58 . In order to understand the mechanisms and consequences of epigenetic changes, it is important to first understand the organizational structure of nuclear DNA and chromatin.
Nuclear DNA is packaged into a histone-protein complex called chromatin (Fig. 2) . The basic subunit of chromatin is the nucleosome, which comprises an octamer of two copies of each of the core histone proteins H2A, H2B, H3 and H4, wrapped by 147 bp of chromosomal DNA 59, 60 . Epigenetic modifications affect chromatin structure and the expression of genes by either covalently modifying DNA or histone proteins to affect the binding of transcriptional regulators to DNA or through actions of ncRNAs. The most well-studied epigenetic marks include DNA methylation of cytosines, histone post-translational modifications (PTMs) and ncRNAs. Whereas 'epigenetics' refers to epigenetic modifications that occur in single genes or sets of genes, 'epigenomics' refers to the broader, genome-wide profiles and effects of these modifications. The epigenome therefore collectively dictates cell identity and the gene expression and phenotypes of specific cells. Epigenetic control of gene expression is important in several important biological processes, including development, cellular identity, genomic imprinting and cell differentiation. In the context of diabetes mellitus, epigenetic control of gene expression can mediate cellular responses to environmental factors and contributes to the differential susceptibility of monozygotic twins to diabetes mellitus and its complications.
Changes in the environment, including nutritional changes, can either transiently or chronically affect epigenetic states 54, 61, 62 . Furthermore, as epigenetic marks are heritable, maternal behaviour and nutritional status (that is, undernutrition or overnutrition) can induce intrauterine and early postnatal epigenetic changes that might predispose offspring to metabolic diseases 54, 62 . A number of studies have also highlighted a connection between low birthweight, poor nutrition, low nephron endowment and the development of renal disease -a series of events most likely mediated by epigenetic factors 63 . Notably, the role of epigenetics in mediating the effects of maternal nutritional status on kidney development was elegantly demonstrated in a 2018 study 64 , which showed that in a rat model of intrauterine growth restriction, kidneys of postnatal day 1 pups had reduced weight as well as pronounced DNA hypomethylation relative to controls. In mice, deletion of Dnmt1, which encodes the maintenance DNA methyltransferase 1, in nephron progenitor cells phenocopied the effects of intrauterine growth restriction, with reduced nephron number at birth and reduced expression of genes critical for nephrogenesis 64 , supporting a role for DNA methylation in mediating the effects of altered nutritional status on renal programming.
Epigenetics has also been strongly associated with the risk of both T1DM and T2DM [65] [66] [67] , but this aspect is not discussed in this Review.
DNA methylation in DKD. DNA methylation is mediated by DNA methyltransferases DNMT1 and DNMT2 and the DNMT3 family members DNMT3a, DNMT3b and DNMT3-like (DNMT3L). DNMT3a and DNMT3b mediate de novo DNA methylation (that is, the establishment of new DNA methylation patterns), whereas DNMT1 is a maintenance methyltransferase that copies the methylation pattern of parental DNA strands 60 . On the other hand, the function of DNMT2 is relatively less clear, with data suggesting that it serves more as a tRNA methyltransferase 68 . DNA methylation can be reversed by ten-eleven translocation (TET) proteins, which convert 5-methylcytosine to 5-hydroxymethylcytosine 69 . Methylation of DNA at gene promoter regions can repress gene expression through various mechanisms, The pathophysiology of diabetic kidney disease (DKD) is complex and involves interactions between genetic factors, epigenetic factors and the environment. High glucose levels in the context of diabetes mellitus, together with hypertension and hyperlipidaemia, induce the expression of growth factors, angiotensin II (AngII), cytokines and advanced glycation end products (AGEs) and produce oxidized lipids, mitochondrial dysfunction and oxidative and endoplasmic reticulum (ER) stress. Growth factors, such as transforming growth factor-β1 (TGFβ1), stimulate signal transduction pathways, including those involving MAPK and AKT kinases that activate downstream transcription factors, such as upstream stimulatory factors, SMADs, AP1 and the ER stress-related transcription factor CHOP (C/EBP homologous protein). They also affect epigenetic processes, including DNA methylation, histone modifications and the expression of non-coding RNAs (microRNAs and long non-coding RNAs (lncRNAs)), resulting in altered chromatin accessibility and/or altered expression of target genes. Interactions between transcription and epigenetic factors lead to the persistent activation of signalling pathways, which might contribute to the phenomenon of metabolic memory , whereby exposure to high glucose levels leads to continued detrimental effects, even after glycaemic control has been established. Together, these conditions promote inflammation, fibrosis and glomerular hypertrophy , which are hallmarks of DKD.
DNA methylation
An epigenetic modification that adds a methyl (CH 3 ) group to DNA, typically at the 5′-cytosine (C) of Cpg dinucleotides.
Histone post-translational modifications (PTMs). Covalent modifications (for example, methylation, phosphorylation and acetylation) on histone residues that facilitate epigenetic regulation of gene expression by altering chromatin structure or recruiting chromatin modifiers.
NATuRe RevIewS | NEPhRoLoGy including the recruitment of transcriptional repressors and by interfering with transcription factor binding, whereas methylation of DNA at gene bodies or transcribed regions can regulate the elongation phase of transcription and alternative splicing 60 
.
Several experimental and clinical studies indicate the existence of links between CpG DNA methylation and DKD. For example, experimental models support the involvement of DNA methylation in glomerular and proximal tubular epithelial cell functions, including filtration, glucose and solute handling 70 ; dysregulation of critical genes associated with these processes has a critical role in the pathogenesis of CKD and DKD. In models of TGFβ1-induced renal fibrosis, upregulation of TGFβ1 induced hypermethylation of the Rasal1 promoter, leading to reduced expression of this Ras-GTP suppressor and increased Ras-GTP signalling, increased fibroblast activation and fibrosis 71 . Changes in Rasal1 promoter DNA methylation were reversed by TET3-mediated hydroxymethylation, with a concomitant reduction in fibrosis 72 . In another study, mice with streptozotocin-induced albuminuria showed decreased expression of the histone deacetylase (HDAC) SIRT1. Interestingly, tubule-specific overexpression of SIRT1 prevented albuminuria by inducing hypermethylation of the Cldn1 gene (as SIRT1 deacetylates and activates DNMT1), leading to downregulation of the tight junction protein claudin 1, in podocytes, suggesting crosstalk between podocytes and proximal tubules through epigenetic mechanisms 73 . On the other hand, mice with proximal tubule-specific deletion of Sirt1 showed aggravation of albuminuria in association with reduced Cldn1 methylation, enhanced histone acetylation and upregulation of claudin 1 (ReF. 73 ). These and other studies showing the protective effects of SIRT1 in DKD have prompted further evaluation of SIRT1 as a therapeutic target for DKD 73 . In the db/db mouse model of DKD, transcriptional repression of the transcription factor KLF4 was associated with increased DNA methylation at the promoter region of the gene that encodes nephrin, along with podocyte apoptosis and protein uria 74 . Another in vivo study showed that the promoter region of Agt, which encodes angiotensinogen and is associated with hypertension and CKD, exhibited DNA hypomethylation and acetylation of histone H3 at lysine 9 (H3K9ac) along with increased expression in early stages of DKD in db/db mice. These epigenetic marks were resistant to treatment with the antidiabetic drug pioglitazone, suggesting that conventional therapies might be unable to reverse epigenetic marks (as discussed later) 75 . A 2017 study demonstrated that cultured proximal tubule cells exposed to high glucose, and kidneys from streptozotocin-treated mice, exhibited DNA hypomethylation of MIOX, associated with enhanced expression of its encoded protein, myo-inositol oxygenase. Hypomethylation of MIOX was associated with enhanced binding of transcription factor Sp1 to its promoter and the expression of genes involved in oxidative stress, hypoxia and fibrosis 76 . In a further study, levels of Sp1, NF-κB and DNMT11 were markedly increased in podocytes from diabetic db/db mice; inhibition of DNMT1 with 5-azacytidine, 5-aza-2ʹ-deoxycytidine or Dnmt1 small interfering RNA induced renal protection, suggesting that epigenetic regulation of the Sp1-NF-κB-DNMT1 signalling pathway might be involved in podocyte injury in DKD 77 . Increased expression of the DNA methylation eraser, TET2, increased expression Chromosomes are composed of DNA-protein complexes called chromatin. The basic subunit of chromatin is the nucleosome, which comprises an octamer of two copies of each of the core histone proteins -H2A , H2B, H3 and H4 -wrapped by 147 bp of chromosomal DNA. Condensed chromatin is generally characterized by promoter DNA methylation and histone methylation, depending on the site of modification on the histone (for example, lysine 9 methylation (K9Me) and lysine 27 methylation (K27Me) on histone H3), resulting in repressed gene expression. Relaxed chromatin is marked by histone lysine acetylation and methylation of lysine 4 on histone 3 (K4Me) in the promoter regions, which enables efficient gene expression. Histone lysine acetylation at the enhancer region also enhances gene expression by interacting with the promoter region through bromodomain-containing proteins (BRD) and other proteins. RNA methylation is a form of epigenetic regulation related to the translation and degradation of RNAs. 79 . In this study, treatment of mesangial cells with hydrogen peroxide also induced demethylation of the Tgfb1 promoter, leading to upregulation of Tgfb1 expression, suggesting that reactive oxygen species might mediate mesangial fibrosis in DKD through aberrant DNA methylation of the Tgfb1 locus.
DNA methylation EWAS
An increased appreciation of the contribution of epigenetic mechanisms to human disease, including complications of diabetes, has led to a surge in epigenome-wide association studies (EWAS) of DNA methylation status in populations of patients with CKD and DKD (TAble 1) .
In a 2010 case-control study of 192 patients with T1DM 80 , researchers used the Illumina HumanMethylation27 BeadChip (which assesses ~27,000 CpGs across the genome) to compare DNA methylation levels from the genomic DNA of patients with and without DKD. Nineteen CpGs correlated with time to DKD development, including one near UNC13B, which contains an SNP associated with DKD. In another early study, DNA from saliva was used to compare DNA methylation levels in >14,000 genes in AfricanAmerican and Hispanic patients with diabetes mellitus (3 with T1DM and 21 with T2DM) and ESRD with those of patients with diabetes mellitus but no DKD 81 . Interestingly, 21% of the 187 differentially methylated genes had been previously associated with CKD or DKD, suggesting potential functional relevance of these findings to disease pathogenesis. Another study that used the Illumina HumanMethylation27 BeadChip to assess epigenetic markers of renal function in 972 African Americans (including 298 with DKD) from the Genetic Epidemiology Network of Arteriopathy (GENOA) study 82 found that 24 of the top 30 DNA methylation markers significantly associated with estimated glomerular filtration rate (eGFR) were related to ageing, inflammation or cholesterol pathways.
The development of improved DNA methylation arrays, high-throughput sequencing technologies and powerful approaches for data analysis have prompted additional EWAS in DKD and CKD populations over the past ~10 years with the aim of improving disease prognosis and patient classification 83 . In the first EWAS of kidney biopsy samples, DNA methylation profiling of microdissected tubules from patients with DKD or non-diabetic CKD compared with those of control individuals without renal disease revealed significant differences between the two groups 84 . Notably, the differentially methylated regions localized mostly to enhancers and were enriched in binding sites for important kidney-specific transcription factors. Key genes associated with renal fibrosis, such as collagens, showed differential methylation patterns that correlated with gene expression. Another study used the Illumina HumanMethylation450 BeadChip (which assesses ~450,000 CpG features across the genome) to profile DNA methylation in 255 T1DM patients with CKD (including 113 with DKD) and 152 controls (including 113 T1DM) without renal disease 85 . The researchers then evaluated the biological and functional relevance of the differentially methylated genes using in silico analyses based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database of pathways. These analyses led to the identification of 23 genes that had significant methylation changes associated with CKD and suggested a potential functional role for DNA methylation changes in influencing CKD development.
Mitochondrial function has an important role in the pathogenesis of DKD. A study of DNA methylation alterations in genes related to mitochondrial function in patients with DKD compared the methylation of blood DNA from 196 patients with T1DM and DKD to that of 246 patients with T1DM but with no renal disease 86 . The researchers identified 54 CpG sites where methylation changes were significantly associated with DKD using both the HumanMethylation27 and HumanMethylation450 BeadChips; in a further subanalysis, 46 of the top-ranked variants for DKD, including several genes related to mitochondrial function, were differentially methylated in patients with ESRD relative to those without renal disease.
An analysis of DNA methylation levels in participants from the Chronic Renal Insufficiency Cohort (CRIC) with the lowest and highest rates of eGFR decline (that is, those with stable renal function versus rapid decliners) using the HumanMethylation450 BeadChip identified associations between methylation at CpG islands in certain genes and renal fibrosis 87 . Participants (20 patients, including 10 with DKD) with stable renal function had greater DNA methylation of NPHP4, IQSEC1 and TCF3 than rapid decliners (20 patients, including 10 with DKD). Genes associated with oxidative stress and inflammation were also differentially methylated between the two groups. These data support a role for epigenetic changes in renal function decline in patients with CKD. Replication studies are needed to validate these findings and to determine whether these key epigenetic differences exist in patients with DKD, although these CKD cohorts had a considerable number of participants with DKD.
The role of DNA methylation in the trans-generational inheritance of metabolic diseases has been well studied because of the ability of diet and the environment to alter epigenetic marks at genes associated with metabolic functions 54, 62, 88 . A study of the effects of fetal exposure to hyperglycaemia on kidney development and function 89 used the HumanMethylation27 BeadChip to examine leukocyte DNA methylation in 29 adult non-diabetic offspring of mothers with T1DM (the case group) and 28 non-diabetic offspring of fathers with T1DM (the control group). Differentially methylated CpGs were not located in any gene directly related to kidney development or function, but DNMT1, a key DNA methyltransferase involved in gene regulation in early development, showed reduced DNA methylation in the case group, prompting the researchers to conclude that
Genomic imprinting
A phenomenon whereby maternal and paternal chromosomes (or genes) are differentially marked and either maternal or paternal genes are selectively suppressed. DNA methylation is a key mark for genomic imprinting.
Elongation
A process of copying DNA into the growing RNA chain by RNA polymerase during the elongation phase of transcription.
Alternative splicing
A process that allows multiple mRNAs to be transcribed from a single gene. Usually, certain exons of a gene are included or excluded from the final processed mRNA.
Histone deacetylase (HDAC) . enzyme that removes the acetyl group from histones.
Epigenome-wide association studies
(eWAS). Cataloguing of epigenetic marks (typically focused on DNA methylation) across the genomes of multiple individuals that are associated with a specific phenotype.
NATuRe RevIewS | NEPhRoLoGy T1DM and exposure to hyperglycaemia in utero might predispose offspring to changes in kidney function via pathways related to imprinting. Additional studies in larger cohorts are needed to strengthen these conclusions and determine whether kidney-specific processes are also involved. Many of the early EWAS were limited by small sample sizes, cross-sectional design with no longitudinal follow-up, lack of replication samples and/or the presence of comorbidities in the patient population under study. A 2017 EWAS 90 assessed whole-blood DNA methylation profiles associated with kidney function in patients from the Atherosclerosis Risk in Communities (n = 2,264, including 586 patients with diabetes) and Framingham Heart (n = 2,595, including 394 patients with diabetes) studies, representing the largest EWAS of a CKD cohort to date. Using the HumanMethylation450 BeadChip, the researchers identified 19 CpGs associated with eGFR and CKD, 5 of which were associated with renal fibrosis and showed concordant DNA methylation changes in renal cortical biopsy samples. The top CpGs mapped to enhancer regions; moreover, the researchers identified methylation at a CpG site, cg19942083, in PTPN6 that was associated with low renal PTNP6 expression, higher eGFR and reduced renal fibrosis, implying that PTPN6 could be further evaluated as an epigenetic biomarker for fibrosis and/or CKD and that locus-specific DNA methylation changes might cause CKD by altering the expression of functionally relevant genes. Notably, the data also show the utility of non-invasive blood-based DNA methylation profiling to screen for kidney-disease-specific targets. They also observed significant enrichment of eGFR-associated CpGs in regions that bind to the transcription factors EBF1, EP300 and CEBPB. In addition, they used epigenome data from eNCODe to determine putative functions of these CpGs; the presence of active enhancers around the CpGs implied that they are associated with gene expression. This well-designed EWAS has several key strengths, including its large sample size, use of appropriate methodologies to correct for white blood cell subtype composition, the evaluation of important kidney phenotypes, the use of an ethnically diverse population, its replication of findings in an independent cohort and its rigorous analytical methods. Future studies are needed to stratify data obtained by this study according to diabetes status to identify methylation changes that are also specific to DKD. Nevertheless, many of the data analyses and covariate correction approaches used in this study will likely inform future EWAS efforts to establish epigenetic markers of renal function in patients with CKD and DKD.
The Pima Indians of the southwestern United States have among the highest incidence of T2DM of any population in the world and have a very high incidence of DKD. A 2018 study that examined leukocyte DNA methylation patterns at ~400,000 CpG sites in 181 Pima Indians with T2DM identified an association between methylation at 77 CpG sites and eGFR decline over a 6-year period 91 . Furthermore, 3 of these 77 probes showed directionally consistent associations with fibrosis in matched kidney tissue, adding to the growing number of reports supporting a role of DNA methylation and epigenetic variations as potential biomarkers of DKD progression.
EWAS: challenges and opportunities.
A limitation of EWAS of renal phenotypes is the paucity of available renal biopsy material. In one approach to circumvent this limitation, a 2018 study used an in silico analytic approach to identify renal-compartment-specific genes and methylated sites related to DKD. The researchers mined the publicly available Gene Expression Omnibus (GEO) database for glomerular and tubular data sets, then enriched their data set by performing functional analyses using gene ontology and KEGG analyses and integrated the expression data with HumanMethylation27 BeadChip data 92 . This process led to the generation of glomerular-specific and tubular-specific networks of genes that were associated with related tissue-specific functions in DKD pathogenesis, including mitochondrial function and acid-base regulation 92 . With increasing availability of transcriptome, epigenome and other data sets from numerous clinical trials and consortia, as well as more powerful data integrative tools and reference data sets, it is likely that such in silico approaches will help accelerate new discoveries in DKD epigenome research.
Because epigenetic marks affect gene expression in a cell-specific manner, early EWAS were often confounded by the cellular heterogeneity of the samples. This challenge has been addressed to some extent by the adoption of computational deconvolution approaches that use published reference DNA methylation data sets to adjust for differences in the cell composition between samples from different participants so that methylation changes can be corrected for any variation caused by cell-type composition 93 . In addition, efforts have been made to compare EWAS findings from whole-blood genomic DNA with candidate DNA methylation and gene expression changes in matched renal biopsy samples in the same patient to determine the extent to which changes in blood reflect those in the kidney 90 . Another challenge is the limited genome coverage provided by the HumanMethylation27 and HumanMethylation450 BeadChips. Although these BeadChips have been used extensively for populationbased studies, they cover only a small fraction of the genome with little coverage of enhancer regions and might therefore miss important epigenetic changes. The more recently developed Illumina EPIC arrays cover nearly 850,000 CpG sites and have many improved features, including coverage at many enhancers 94 . Sequencing methods, including methylated DNA immunoprecipitation sequencing (Me-DIP-seq), reduced representation bisulfite sequencing (RRBS-seq) and whole-genome bisulfite sequencing, are also increasingly being used to identify more numbers of differentially methylated sites across the genome, facilitated by steadily decreasing costs. These sequencing approaches, especially whole-genome bisulfite sequencing, are powerful and not only can uncover differential changes throughout the genome but also can be combined with in silico bioinformatics and data analysis packages, 
Reduced representation bisulfite sequencing
(RRbS-seq). A technique for analysing the genome-wide DNA methylation profiles with single-nucleotide resolution at relatively low cost. it combines restriction enzyme and bisulfite sequencing to enrich (~1% of genome) for areas of the genome with a high Cpg content.
Whole-genome bisulfite sequencing
The gold standard method for the analysis of DNA methylation of single cytosines at base resolution in the whole genome. it involves next-generation sequencing of bisulfite-converted DNA. Sodium bisulfite converts unmethylated cytosine into uracil, which eventually will appear as thymine after sequencing. Methylated cytosines appear as cytosine.
NATuRe RevIewS | NEPhRoLoGy as well as publicly available omics data sets, for integrative analyses to obtain unprecedented new biological data. This information in turn can accelerate the discovery of disease-relevant loci and drug targets through associations with clinical phenotypes and biomarkers in biofluids (serum and urine) and can identify patient-specific variations for personalized medicine 95 . As mentioned earlier, given that most disease-associated SNPs identified by GWAS are present in non-coding regions of the genome, identification of epigenotype variations using EWAS can complement genotype variations uncovered by GWAS and provide powerful information about disease susceptibility and causality. In addition, advances in single-cell (transcriptome and epigenome) sequencing of multiple kidney cell types will greatly aid future EWAS efforts 96 . Exciting reports of single-cell and single-nucleus sequencing of mouse and human kidney cells have already uncovered cell types related to specific kidney diseases, which is relevant to the study of epigenetics because epigenetic marks regulate the expression of genes in specific cell types -for example, podocytes, endothelial cells and tubular cells [97] [98] [99] [100] . Thus, a combination of GWAS, EWAS and single-cell or single-nucleus sequencing, along with integrative analyses with other omics data sets, has the potential to uncover novel new causal genes or loci associated with DKD and to determine the role of epigenetic changes in regulating the expression of these genes. Furthermore, the ability to control the epigenetic changes at these newly identified genes and loci might provide a novel therapeutic approach for treating DKD and altering metabolic memory.
Histone modifications
PTMs of nucleosomal histone proteins in chromatin regulate gene expression and are an important component of epigenetic regulation 59 ( Fig. 2) . Genome-wide profiling of modified histones using c hromatin immunoprecipitation (ChiP) followed by sequencing (ChIP-seq) has shown that specific types of histone modifications are enriched in specific genomic locations such as regulatory regions (enhancers and promoters), transcriptionally repressed regions, transcriptional start sites and actively transcribed regions 101 . The major histone PTMs are lysine acetylation, methylation and ubiquitylation; serine and threonine phosphorylation; and arginine methylation 59, 102 . Histone acetylation can unwind and relax chromatin to enhance gene expression by various mechanisms that facilitate access of transcription factors and cofactors to promoter and enhancer regions, leading to transcription initiation and elongation through nucleosome remodelling 59 ( FigS 2,3) . In general, histone acetylation is enriched at promoters and enhancers of actively transcribed genes and reduced in repressed genomic regions. By contrast, the location of histone methylation varies. For example, monomethylation, dimethylation or trimethylation of H3 at lysine 4 (H3K4me1, H3K4me2 and H3K4me3, respectively) and dimethylation or trimethylation of H3 at lysine 36 (H3K36me2 and H3K36me3, respectively) are enriched at transcriptionally active genome regions, whereas trimethylation of H3 at lysine 9 (H3K9me3), trimethylation of H3 at lysine 27 (H3K27me3) and trimethylation of H4 at lysine 20 (H4K20me3) are enriched in repressed regions 59 , and histone monomethylation of H3 at lysine 4 (H3K4me1) is enriched at enhancer regions 103 . Active enhancers are marked by enrichment of acetylated H3 at lysine 27 (H3K27ac) along with mediator complexes and transcription factors. Super-enhancers, which are long stretches of enhancers enriched for binding motifs of transcription factors, are cell-type-specific; hence, examination of their differential regulation by epigenetic marks could provide a wealth of information about cell-specific functional alterations in disease states 104 . Poised promoters in developmental genes are enriched with bivalent chromatin modifications, for example, both active (H3K4me3) and repressive (H3K27me3) marks, which allow dynamic changes in the expression of developmentally regulated genes to occur (that is, silenced to highly expressed) in a stage-specific manner 101, 102 . Although the role of DNA methylation in epigenetic transmission and heredity is generally better accepted than that of histone modifications, some repressive histone PTMs can be epigenetically inherited 105 . The histone acetyltransferases p300 and CREBbinding protein (CBP) are transcriptional co-activators and catalyse histone acetylation; HDACs and sirtuins can act as transcriptional co-repressors and remove acetylation marks from histones 59, 102 . Histone lysine methyltransferases (HMTs) catalyse lysine methylation whereas histone lysine demethylases (KDMs) remove methyl groups from histones 59 . HMTs and KDMs use specific lysine residues as substrates 106 and can also target non-histone proteins. Acetyltransferases and methylases are called epigenetic writers; deacetylases and demethylases are called epigenetic erasers; and proteins such as the bromodomain-containing proteins (BRDs; for example, BRD4), which recognize acetylated proteins at promoters and enhancers and have an active role in gene transcription, are called epigenetic readers [107] [108] [109] . Studies of histone PTMs at key metabolic genes suggest that their epigenetic regulation has a critical role in the pathogenesis of T1DM, T2DM, obesity and the metabolic syndrome 65, 110, 111 . These findings indicate that histone PTMs are also involved in diabetic complications -a proposal supported by preclinical studies of DKD. For example, induction of the pro-fibrotic genes Pai1 (which encodes plasminogen activator inhibitor 1) and p21 in cultured rat mesangial cells in response to TGFβ or high glucose is associated with enrichment of H3K9ac and H3K14ac and the presence of p300 and CBP at SMAD and Sp1 binding sites in the promoters of these genes 112 . ChIP assays of glomeruli of diabetic mice showed that increases in Pai1 and p21 expression in vivo were associated with a similar enrichment of H3K9ac and H3K14ac at their promoters. Furthermore, increased expression of Pai1, Col1a1 (which encodes the collagen type I α1 chain) and Ctgf (which encodes connective tissue growth factor) induced by TGFβ1 was accompanied by enrichment of active histone methylation (H3K4me1, H3K4me2 and H3K4me3) and decreased repressive marks (H3K9me2 and H3K9me3) at their promoters, together with increased occupancy Chromatin immunoprecipitation (ChIP) followed by sequencing (ChiP-seq). A method to analyse protein interactions with DNA. ChiP-seq combines ChiP using specific antibodies to a target protein followed by high-throughput DNA sequencing to identify the binding sites of DNA-associated proteins in a genome-wide fashion.
Mediator complexes
A multiprotein complex that is required for gene transcription by RNA polymerase ii and functions as a transcriptional co-activator in eukaryotes. Subunits of the complex relay information from signals and transcription factors to the RNA polymerase ii machinery to control the expression of specific genes.
Poised promoters
Promoters that are defined by the simultaneous presence of histone modifications associated with both gene activation and repression (bivalent). They are frequently found at the promoters and enhancers of developmental and lineage-specific genes.
www.nature.com/nrneph of the HMT SET7 (ReF.
113 ). Consistent with these findings, exposure of cultured rat mesangial cells to 12(S)-hydroxyeicosatetraenoic acid, which is increased in DKD, induced similar effects to TGFβ1 on these histone PTMs and pro-fibrotic genes, and the effects of this oxidized lipid on fibrosis were also mediated in part via SET7 (ReF.
114
).
Changes in the expression of key DKD-associated ncRNAs can also be regulated by histone PTMs. TGFβ1-induced histone acetylation (H3K9ac, H3K14ac As discussed below, miR-192 is upregulated by TGFβ1 and has an important role in renal fibrosis and DKD pathogenesis.
In vivo studies in the db/db model of T2DM have demonstrated that several chromatin histone PTMs occur in the promoters of Pai1 and Ager (which encodes the AGE-specific receptor, RAGE) in glomeruli, together with increased recruitment of RNA polymerase II, suggesting that both active and repressive epigenetic marks cooperate to promote chromatin unwinding and enhance the recruitment of transcription factors to these DKD-associated genes. Of note, administration of the ARB losartan ameliorated key indices of DKD and reduced H3K9ac enrichment at Pai1 and Ager promoters but did not reverse other diabetes-induced histone PTMs in these mice 117 . This incomplete amelioration of epigenetic changes following treatment could be a reason why some patients do not respond well to routine DKD drugs such as ARBs. Combination therapy with conventional therapies and drugs that target epigenetic processes could be a viable option for such patients 24 . In another study, increased recruitment of RNA polymerase II and enriched H3K4me2, but diminished H3K27me3, correlated with the expression of DKD-related genes in mouse and rat models of T1DM. However, some differences were identified in the expression of a few genes (for example, Mcp1 and Lamc1) and epigenetic regulators (Ezh2 K27 methylase and the corresponding demethylase) between rats and mice, suggesting that some epigenetic changes could be species-specific 118 . This possibility should be taken into consideration when translating findings from epigenetic studies in animals to human DKD. Podocyte-specific deletion of the HMT EZH2 decreased H3K27me3 levels at the promoter region of Jag1, which encodes the Notch ligand Jagged1, which increased Jag1 expression and sensitized mice to glomerular disease in three injury models, including diabetic db/db mice 119 . By contrast, inhibition of the KDMs Jmjd3 (also known as Kdm6b) and Utx (also known as Kdm6a) increased H3K27me3 levels and attenuated glomerular disease in these models. Lower H3K27me3 levels and higher UTX levels were also detected in glomerular podocytes from humans with DKD, suggesting that induction of JAG1 by histone demethylation through the actions of UTX1, and activation of Notch signalling in podocytes, could be involved in the development of glomerular dysfunction in human DKD 119 . Increased renal inflammation as a result of macrophage infiltration contributes to the pathogenesis of DKD. Histone modifications have been implicated in mediating the activation of NF-κB and other inflammatory factors in vascular cells and monocytes in response to high glucose 120, 121 . Epigenome profiling studies have demonstrated differences in H3K4me2 and H3K9me2 marks at genes associated with diabetes and inflammation in high-glucose-treated monocytes, and in blood monocytes and lymphocytes from patients with T1DM Fig. 3 | Epigenetic mechanisms of metabolic memory. Hyperglycaemia alters histone modifications and DNA methylation status, resulting in a change in chromatin structure from condensed (marked by DNA methylation, methylation of lysine 9 on histone 3 (K9Me) and methylation of lysine 27 on histone 3 (K27Me)), which is associated with repressed gene expression, to relaxed (marked by histone lysine acetylation and methylation of lysine 4 on histone 3 (K4Me)) to induce the expression of pathogenic genes. Acetylation relaxes chromatin and enhances gene expression through various mechanisms, including by facilitating the release of transcriptional repressors from condensed chromatin. Once established, the chromatin status (including DNA methylation and histone modification status) is maintained, even after normoglycaemia has been established, by the administration of insulin or antidiabetic drugs, with persistent expression of pathogenic genes, in a phenomenon called 'metabolic memory'. This epigenetic memory could potentially be erased using epigenetic drugs or by inducing locus-specific changes in histone modifications or DNA methylation through approaches such as gene editing directed by guide RNAs complementary to a specific locus.
diabetes, compared with those in normoglycaemic controls [121] [122] [123] . The HMT SET7 promotes methylation of H3K4 and co-activates inflammatory genes downstream of NF-κB in monocytes 124 . Given the above-described role of SET7 in promoting the expression of pro-fibrotic genes in mesangial cells exposed to TGFβ, these findings suggest that this HMT might have a general role in regulating the expression of key pathological genes in various cell types, including monocytes and endothelial and mesangial cells associated with diabetic complications, and support efforts to explore small-molecule inhibitors of SET7 (ReF.
125
Together, these data from cell, animal and clinical models clearly suggest that epigenetic regulation of DKD-related genes through histone PTMs in addition to DNA methylation has a critical role in the pathogenesis and progression of DKD (Fig. 1) . Population-based EWAS of histone PTM profiles are less common than those of DNA methylation status because they require relatively large amounts of high-quality ChIP-grade antibodies, fresh tissues or blood samples and larger sample volumes. However, the increased availability of online data sets of enhancers with histone PTM profiles and of the chromatin states of multiple cell types should prove useful for integration with data from RNA sequencing and DNA methylation and should considerably aid interpretation of the functional relevance of epigenome changes to the aetiology and pathogenesis of DKD for future development of biomarkers and drug targets.
Epigenetics in metabolic memory
Epigenetic mechanisms, including DNA methylation and histone PTMs, have been implicated in the metabolic memory of diabetic complications, including DKD (Fig. 3) . Analysis of chromatin and DNA in blood monocytes and lymphocytes of patients with T1DM who participated in the DCCT and EDIC trials 126, 127 showed significant enrichment of H3K9ac at key inflammatory genes in monocytes from patients who received conventional therapy during DCCT and experienced progression of nephropathy or retinopathy (cases) during subsequent EDIC follow-up compared with levels in patients who received intensive glycaemic control during DCCT and who did not experience progression of nephropathy and retinopathy (controls) during EDIC 126 . Furthermore, this study identified a significant association between HbA 1c level and H3K9ac, suggesting that H3K9ac might contribute to metabolic memory in patients with T1DM
126 owing to hyperglycaemia-induced sustained chromatin relaxation at susceptible genomic regions via histone hyperacetylation.
Another study of the DCCT and EDIC cohort 127 used the HumanMethylation450 BeadChip to profile DNA methylation in genomic DNA from whole blood taken at DCCT baseline and from blood monocytes obtained ~17 years later during the EDIC phase from the same set of patients. After adjustment for multiple covariates, including age, gender and cell-type composition, the researchers identified a set of 150-250 regions that were differentially hypomethylated or hypermethylated in cases (patients who received conventional therapy during DCCT and experienced progression of nephropathy or retinopathy by EDIC year 10) and controls (patients who received intensive glycaemic control during DCCT and did not experience progression of nephropathy or retinopathy during EDIC). Notably, 12 differentially methylated loci were common in both whole blood and monocytes, including hypomethylation in cases at the 3′-untranslated region (UTR) of TXNIP, which encodes thioredoxin-interacting protein and is associated with hyperglycaemia and related complications including DKD 127, 128 . Similarly, exposure of cultured THP-1 human monocytes to high glucose induced persistent hypomethylation at the 3ʹ-UTR of TXNIP. Furthermore, analyses of the association between DNA methylation in whole blood and monocytes from each DCCT patient (in samples collected ~17 years apart) and mean HbA 1c levels for those patients measured at multiple time points from the start of DCCT to the time of monocyte collection during EDIC years 16-17 led to the identification of a set of differentially methylated loci (including the TXNIP 3′-UTR) in both whole blood and monocyte DNA that were similarly associated with prior HbA 1c level, meaning that the researchers identified associations that persisted for ~17 years in the same patient. These findings of a persistence of memory in an epigenetic signature and association with prior history of hyperglycaemia strongly support a role for epigenetic mechanisms in metabolic memory. Interestingly, hypomethylation of TXNIP at the same site (cg19693031) has also been observed in other cohorts, in association with higher fasting blood glucose levels and lipidaemia 129 , indicating that metabolic abnormalities and diabetes might promote similar DNA methylation changes at specific genomic loci that in turn lead to sustained complications.
Studies of experimental models also support a role for epigenetic mechanisms in metabolic memory. One study showed that, compared with vascular smooth muscle cells (VSMCs) from aortas of non-diabetic heterozygous db/ + mice, VSMCs from diabetic db/db mice showed high expression of inflammatory genes, associated with lower levels of the HMT SUV39H1 and lower levels of promoter H3K9me3 -a repressive mark 130 . This difference in histone methylation persisted even after the VSMCs had been cultured for several passages. VSMCs from diabetic db/db mice also showed upregulation of miR-125b, which targets SUV39H1, demonstrating that miRNAs are key regulators of epigenetic factors in metabolic memory 130, 131 . In another study, endothelial cells cultured for short periods under conditions of high glucose exhibited persistent induction of the NF-κB subunit p65, indicative of inflammation, accompanied by sustained enrichment of H3K4me1 and the corresponding HMT SET7 at the p65 promoter, long after normalization of glucose levels 132, 133 . In parallel, the researchers observed sustained and persistent increases in the expression of NF-κB-dependent inflammatory genes Ccl2 (also known as Mcp1) and Vcam1. These cell culture data demonstrate the existence of metabolic memory mediated by epigenetic mechanisms in cultured cells and are supported by in vivo findings from studies of glucose-infused normal mice and in diabetic mice prone to atherosclerosis [132] [133] [134] [135] . Similar evidence of www.nature.com/nrneph metabolic memory has also been reported in experimental models of diabetic retinopathy and cardiovascular disease 136 , suggesting that metabolic memory is an important component of the epigenetic changes that occur in diabetes and that it has consequences for disease outcomes and response to treatment.
RNA modifications in DKD
In addition to DNA, RNA can also be epigenetically modified (Fig. 2) . RNA methylation regulates gene expression by altering RNA stability and degradation. The methyltransferase complex METTL3-METTL14-WTAP converts adenosine to N6-methyladenosine (m6A) on RNA 137 . In human stem cells, activation of SMAD2 and/or SMAD3 by TGFβ signalling promotes binding of the m6A methyltransferase complex to transcripts involved in early cell fate decisions: the rapid downregulation (that is, degradation) of these transcripts enables the timely exit of cells from pluripotency 138 . Given the major role of TGFβ1 in DKD, similar epigenetic crosstalk between TGFβ, SMAD2 and/or SMAD3 and m6A methyltransferase could be involved in DKD. Indeed, according to the Nephroseq database, the expression of METTL3, METTL14 and WTAP is lower in glomeruli from diabetic mice, patients with CKD and patients with focal segmental glomerulosclerosis than in healthy control samples, suggesting that negative feedback of m6A methylation could be disrupted, resulting in sustained expression of TGFβ and SMAD2 and/or SMAD3. This mechanism might also contribute to the persistent expression of genes associated with DKD.
Non-coding RNAs
Data from ENCODE and other consortia show that the majority of the genome is transcribed into RNA, much of which is non-coding 101, 139, 140 . ncRNA includes not only small ncRNAs, such as miRNAs, but also long ncRNAs (lncRNAs), both of which are part of the epigenome and have regulatory functions.
MicroRNAs in DKD.
miRNAs are well-established epigenetic regulators and modulators of gene expression. These endogenous small ncRNAs are 20-25 nucleotides in length and typically silence expression of target genes by hybridizing to the 3′-UTR of target mRNAs, leading to translational repression and/or mRNA degradation 141 . miRNAs are thought to regulate up to 60% of human protein-coding genes. They are generated as relatively long primary transcripts (pri-miRNAs) following transcription by RNA polymerase II in the nucleus, which are then processed to ~70 nucleotide stem-loop structures called precursor miRNAs (pre-miRNAs) by the Drosha-DGCR8 complex. pre-miRNAs are transported to the cytoplasm and processed to mature miRNAs by Dicer. Genetic deletion of Dicer or Drosha in mice results in severe renal phenotypes, including proteinuria, underscoring the functional relevance of miRNAs in the kidney [142] [143] [144] [145] [146] . The first miRNA shown to have a functional role in DKD was miR-192, which acts by targeting key repressors to promote the expression of ECM and collagen and to augment the pro-fibrotic effects of TGFβ1 ( ReFS  30,116,147,148 ). Numerous miRNAs are now thought to regulate key features of DKD, such as podocyte apoptosis, the accumulation of ECM, glomerular and tubular hypertrophy and fibrosis. The roles of miRNAs in DKD have been reviewed elsewhere 14, [149] [150] [151] . Of note, MeCP2 (methyl CpG binding protein 2) supresses miRNA processing through the Drosha-DGCR8 complex 152 and modulates miR-25-NOX4 expression related to oxidant stress in the diabetic kidney 153 , suggesting an interesting connection from DNA methylation to miRNA regulation.
Long non-coding RNAs in DKD. lncRNAs are long transcripts (>200 nucleotides and up to ~100 kb in length) that have many similarities with mRNAs but lack protein-coding (translation) potential 139, 154 . Increasing evidence suggests that lncRNAs have distinct cellular roles that affect various biological mechanisms and processes, including gene transcription, splicing, mRNA stability, epigenetic regulation, cell cycle control, differentiation and the immune response 155, 156 . lncRNAs regulate the expression of local and distal genes through various mechanisms, which include binding and targeting histone-modifying complexes to various loci to affect chromatin states and modulate transcription [155] [156] [157] . lncRNAs also serve as host RNAs for miRNAs and act as modular molecules with individual domains that enable them to specifically associate with DNA, RNA and/or proteins to affect gene expression 28, 30, 31, [156] [157] [158] . Thus, lncRNAs form an integral part of the epigenome. Interest in lncRNAs increased following the discovery that many lncRNAs are dysregulated in human diseases; furthermore, many GWAS studies have observed SNPs in lncRNA loci 155, 159 , underscoring the potential connection of lncRNAs to disease states, including diabetes and its complications.
Reports showing the involvement of lncRNAs in DKD have emerged only in the past few years 160 . A 2009 report showed that key miRNAs (miR-216a and miR-217) with DKD-related functions were induced by TGFβ1 together with their host lncRNA RP23-298H6.1-001 in mesangial cells 28 . Another study in mouse mesangial cells treated with TGFβ1 (mentioned earlier) demonstrated that miR-192 is co-regulated with its host lncRNA CJ241444 through histone acetylation of the lncRNA promoter and the proto-oncogene ETS1, leading to the enrichment of SMADs and upregulation of both the lncRNA and miR-192 (ReF. 30 ). Administration of AngII -a peptide hormone that is associated with renal dysfunction, hypertension and DKD -to cultured VSMCs induced several lncRNAs, including lnc-Ang362, which serves as a host for miR-221 and miR-222, known to promote VSMC proliferation. Findings from this study showed that lnc-Ang362 might drive VSMC proliferation through these miRNAs 161 . Another AngII-induced novel lncRNA called Giver is regulated by the nuclear receptor NR4A3 and promotes oxidant stress and inflammation in VSMCs 162 . Expression of Giver was increased in AngII-infused mice with hypertension, and expression of a human orthologue GIVER was elevated in arteries from patients with hypertension. A further study showed that key lncRNAs induced by AngII overlap with enhancers regulated by AngII in NATuRe RevIewS | NEPhRoLoGy VSMCs; CRISPR-Cas9-mediated deletion of candidate lncRNA-associated enhancers reduced the expression of nearby AngII-regulated genes, demonstrating crosstalk between these two epigenetic systems 163 . The lncRNA plasmacytoma variant translocation 1 (PVT1) is also involved in fibrosis and DKD pathogenesis 164 . The PVT1 locus was first implicated in diabetes-associated ESRD in a GWAS in 2007 (ReF. 165 ).
Several miRNAs that map to the PVT1 locus, including miRs1204-1208, were subsequently shown to be upregulated in human mesangial cells in response to high glucose conditions, inducing the expression of ECM-related genes 166 . Another study found that 21 lncRNAs were upregulated in two models of renal fibrosis but downregulated in SMAD3-knockout mice, indicating a role for TGFβ-SMAD signalling in the regulation of these lncRNAs 167 . A 2016 study identified lnc-megacluster (lnc-MGC), an lncRNA host for nearly 40 miRNAs in the miR-379 cluster, to promote mesangial cell ECM accumulation and hypertrophy in mouse models of early DKD 31 . Expression of lnc-MGC and several of its resident miRNAs were increased in the glomeruli of mouse models of T1DM and T2DM, and in cultured mouse mesangial cells exposed to high glucose and TGFβ1 through mechanisms involving the ER stress-related transcription factor CHOP (C/EBP homologous protein). miR-379 targets (and therefore represses) Edem3, which encodes an inhibitor of ER stress, whereas miR-494, another miRNA in the miR-379 cluster, targets Atf3, a repressor of CHOP. Thus, upregulation of lnc-MGC and this miR-379 cluster can augment ER stress in DKD, which in turn might lead to persistent expression of lnc-MGC and miR-379 cluster miRNAs, continuing the circuits and potentially contributing to metabolic memory 31 (Fig. 4) . Notably, a human orthologue of lnc-MGC is also upregulated in human mesangial cells following exposure to high glucose and TGFβ1 (ReF.
31
). This finding is important because unlike miRNAs, lncRNAs are generally not well conserved across species; therefore, it suggests that this lncRNA cluster could also be relevant to human DKD.
Podocyte foot process effacement, apoptosis and dysfunction are key features of proteinuria and DKD. In mouse podocytes, the lncRNA Tug1 was shown to regulate changes in mitochondrial bioenergetics associated with DKD via interactions with PPARγ co-activator α (PGC1α) and subsequent effects on key PGC1α targets that are important for mitochondrial biogenesis. Mice with diabetes showed downregulation of Tug1; however, overexpression of Tug1 in mice was sufficient to reverse the negative impact of diabetes on mitochondrial function and ameliorate DKD 168 . These data suggest that decreased Tug1 in podocytes in the context of diabetes mellitus reduces mitochondrial function and biogenesis through downregulation of PGC1α target genes.
Several reports have described crosstalk between lncRNAs and miRNAs in the pathogenesis of DKD 169, 170 . For example, the lncRNA Erbb4-IR promotes diabetic kidney injury by hybridizing and inhibiting miR-29b, which targets genes involved in collagen production and ECM accumulation 169 . Downregulation of another lncRNA, Lin01619, promotes oxidative stress and podocyte injury in DKD through reduced sequestering of miR-27a, which inhibits forkhead transcriptional factor FOXO1 and induces ER stress 170 . The lncRNA 1700020I14Rik reduces cell proliferation and fibrosis in DKD through interactions with the miR-34a-5p-SIRT1-HIF1α signalling pathway 171 . Finally, the lncRNA MALAT1 controls renal tubular epithelial pyroptosis in experimental models of DKD by inhibiting the expression of miR-23c. Inhibition of this miRNA leads to increased expression of its gene target Elavl1, which induces pro-inflammatory programmed cell death in injured tubular epithelial cells 172 , further highlighting the numerous mechanisms by which lncRNAs induce tissue injury in DKD.
As mentioned earlier, infiltration of inflammatory cells and inflammation have important roles in DKD. Transcriptional profiling of blood cell samples from patients with T2DM has revealed several dysregulated lncRNAs with potential roles in inflammation and insulin resistance 173 . RNA sequencing of bone marrow macrophages from obese, diabetic db/db mice showed differential expression of several lncRNAs compared with those of control non-diabetic db/ + mice, including increased expression of E330013P06, a pro-inflammatory lncRNA that enhances the formation of foam cells 174 . Levels of E330013P06 were also higher in macrophages from mice fed a high-fat diet and in monocytes from humans with T2DM than in chow-fed and non-diabetic counterparts, respectively. A 2018 study showed that another pro-inflammatory lncRNA (Dnm3os) was similarly upregulated in macrophages of obese and diabetic mice and in monocytes of humans with T2DM 175 . Dnm3os binds to nucleolin, a major nucleolar protein of eukaryotic cells; the available evidence indicates this interaction is disrupted under diabetic conditions 175 . Disruption of Dnm3os-nucleolin binding enables Dnm3os to enhance histone acetylation (H3K9ac) at promoters of key inflammatory genes, increasing their transcription and promoting macrophage dysfunction 175 . Human macrophage lncRNAs have also been associated with cardiometabolic disorders 176 , indicating that macrophages in the circulation might represent a non-invasive source for the identification of lncRNAs associated with inflammation and DKD.
Together, these reports not only highlight the involvement of lncRNAs in the pathogenesis of DKD but also illustrate crosstalk between epigenetic layers (that is, between lncRNAs, miRNAs and chromatin) and provide insights into the signalling circuits these factors trigger to mediate fibrotic events, inflammation and changes in mitochondrial bioenergetics associated with DKD 15, 28, 31, 151, 168, 177 . We expect that future studies will uncover additional lncRNAs related to DKD, including causal SNPs in lncRNA loci.
Epigenetic biomarkers
Early detection of DKD is important for preventing progression to renal failure; thus, predictive biomarkers could have a major clinical impact in the diagnosis and treatment of DKD. Several biomarkers of DKD progression have been reported 178 , with most being proteins, peptides, growth factors and cytokines.
Pyroptosis
A process of pro-inflammatory programmed cell death that is also a form of regulated necrosis, a lytic type of cell death inherently associated with inflammation.
Foam cells
lipid-laden macrophages that serve as the hallmark of early-stage atherosclerotic lesion formation.
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As discussed earlier, EWAS have also identified epigenetic signatures of specific DNA methylation sites and histone PTMs that are associated with key DKD clinical phenotypes, including eGFR, albuminuria and aberrant renal morphology. Such signatures could be developed as predictive biomarkers of DKD development, as has been done in other fields. For example, the methylation status of the gene that encodes insulin has been exploited as a biomarker to examine pancreatic β-cell loss 179 , and tracking methylation patterns in circulating DNA can be used to identify tissue-specific cell death 180 .
As podocytes are observed in the urine of patients with DKD, methylation of podocyte-specific genes in urine could serve as a biomarker of podocyte dysfunction and death. Combining traditional biomarkers (such as urinary albumin, serum cystatin C, serum and urine neutrophil gelatinase associated lipocalin (NGAL), urine kidney injury molecule 1 (KIM1) and urine transferrin) with novel biomarkers (including circulating proteins, DNA and ncRNAs) could greatly enhance the early detection of renal function decline in patients with diabetes mellitus. miRNAs in biofluids (that is, urine, serum and plasma) are already being investigated as non-invasive epigenetic biomarkers of various diseases, including DKD, and remain a very active area of translational research 14, 151 . These ncRNAs are of particular interest as diagnostic biomarkers of DKD owing to their inherent stability in exosomes and biofluids and availability of methods for their detection and quantification. A number of reports have characterized profiles of key miRNAs in urine, urinary sediment and plasma of patients with various kidney diseases, showing varying levels of correlation with nephropathy or fibrosis [181] [182] [183] [184] [185] [186] [187] . Urinary exosomes, which originate from most renal cells, can be extremely valuable for miRNA profiling in renal disorders 186, 188 . Urinary exosomes from patients with T1DM and microalbuminuria, and mesangial cell-derived exosomes from cultured mesangial cells exposed to high glucose levels, showed enrichment for miR-145, which is associated with inflammatory pathways and thus might be a potential biomarker for DKD 189 . Of note, however, the heterogeneity of extracellular vesicles, including exosomes, and the diversity of circulating extracellular RNAs are poorly understood, as are the mechanisms by which they elicit cellular signalling and communication. These limitations have hampered progress in this field, and caution must therefore be taken when evaluating the potential of exosomes and their contents as biomarkers of disease 190 . A study that profiled over 700 miRNAs in the urine of 40 patients with T1DM and various stages of DKD provided strong support for the use of miRNA profiles as molecular predictors of DKD 191 . Other studies have profiled miRNAs in urine, urinary sediment and serum from patients with differing degrees of DKD, fibrosis, renal function decline and albuminuria 181, 184, 187, 189, [192] [193] [194] . For example, one report suggested that TGFβ1-regulated circulating miRNAs can be used as biomarkers of renal function decline and rapid progression to ESRD in patients with T1DM 193 . Another study reported tissue-specific miRNA expression patterns for four types of kidney disease -namely, DKD, focal segmental glomerulosclerosis, immunoglobulin A (IgA) nephropathy and membranoproliferative glomerulonephritissuggesting such patterns could be used as biomarkers for these diseases and provide clues as to the underlying pathological mechanisms 195 . Of note, as miRNAs and DNA are relatively stable in paraffin-embedded sections, archived pathology sections represent a rich resource for the future development of epigenetic biomarkers. Methods to assess circulating lncRNAs in biofluids are also under development, and the utility of lncRNAs as biomarkers of disease is expected to be another active area of research. For example, one study demonstrated the expression of the lncRNA NR_033515 to be significantly higher in the serum of patients with DKD than in controls and to correlate with the severity of DKD and other diagnostic markers of kidney injury such as KIM1 (ReF. 196 ).
Translating epigenetic findings in DKD Targeting epigenetic factors. Currently available therapies for DKD, such as ARBs, show limited efficacy in preventing the progression of renal disease in many patients 24 . Studies in animal models show that these agents are limited in their ability to inhibit or reverse epigenetic changes that occur in the diabetic kidney 14, 117 , suggesting that future therapeutic approaches might require a combination of conventional therapy plus epigenetic agents. The potential reversibility of epigenetic marks provides exciting opportunities for therapeutic intervention.
Some epigenetic drugs are already being used in oncology and neurology and for inflammation and fibrosis 197 , including HDAC inhibitors and DNA methylation inhibitors 198 , suggesting their efficacy could be assessed in DKD. A 2017 computational systems-level network analysis of microarray data from 33 independent HDAC inhibitor studies revealed enrichment of pathways involved in the metabolic syndrome and diabetes mellitus 199 . Integration of these data with ENCODE ChIP-seq data sets suggested that these HDAC inhibitors suppressed gene targets of the transcription factor EP300, which had previously been implicated in the pathogenesis of diabetes. These in silico data were tested experimentally by treating vascular endothelial cells from a diabetic patient with HDAC inhibitors or EP300 inhibitors, which blocked the expression of diabetes-associated EP300 target genes 199 . This type of in silico computational approach could be useful in identifying new drugs for the treatment of diabetes mellitus and DKD and for the identification of drugs that could be repurposed. Although early-generation HDAC inhibitors have been tested in animal models of DKD with some showing beneficial effects 200 , these agents were generally nonspecific; thus, it may be of value to study the efficacy of newer, more selective inhibitors or activators of HDACs. The class III HDAC protein SIRT1 suppresses AGE-induced expression of pro-fibrotic genes via upregulation of an antioxidant gene in glomerular mesangial cells 201 . Administration of the SIRT1 agonist BF175 to diabetic OVE26 mice attenuated kidney injury, suggesting that targeting (that is, upregulating) this HDAC might be of therapeutic value 202 . Inhibitors of the HMT EZH2 have also been studied, mostly in models of renal fibrosis 200, 203, 204 . CRISPR-Cas9 is a tool that enables targeted editing of the genome. Briefly , the Cas9 endonuclease is delivered into cells with a guide RNA (gRNA) that is designed to bind Cas9 and the target gene of interest. Following targeted Cas9 cleavage, the DNA is repaired by the cellular repair machinery (through non-homologous end joining or homology-directed repair). The system can be modified to achieve various outcomes, including locus-specific induction of point mutations or short deletions (part a), the control of expression of specific genes (part b; by fusing Cas9 with transcriptional activators or transcriptional repressors), specific substitutions (part c; for example, by fusing Cas9 to adenine deaminase, which converts adenine (A) to inosine (I), which pairs with cytosine (C) and will be eventually converted to guanine (G) during replication) and replacement of a long fragment of the genome by homology-directed repair (part d), whereby DNA damage (double-strand breaks) induced by the CRISPR-Cas9 system is repaired by a homologous template that is close to the site. In this process, if an extra sequence is inserted between the left arm and right arm of the homologous template (including extra sequences), the targeted sites can be replaced with the desired extra sequence. ss, single-stranded.
As described earlier, AngII-regulated enhancers overlap with key AngII-regulated genes in VSMCs. This study also showed that an inhibitor of the epigenetic reader BRD4, called JQ1, which also inhibits enhancer function, inhibited AngII-regulated genes in vitro and AngII-induced hypertension in mice 163 , again highlighting the translational potential of targeting epigenetic marks for diabetic vascular complications.
Targeting non-coding RNAs. The finding that several miRNAs are dysregulated in DKD suggests they could represent valuable targets for epigenetic therapies 186 . miRNA levels have traditionally been manipulated using antisense miRNAs or miRNA mimics; however, technical advances have led to the development of stable modified nuclease-resistant oligonucleotides that can act as miRNA inhibitors and mimics. These chemically modified oligonucleotides have enhanced target affinity, nuclease resistance in biofluids and bioavailability, with reduced toxicity. miRNAs that are upregulated can be inactivated using miRNA sponges or antisense oligonucleotides or through gene editing. One widely used modification is locked nucleic acid (LNA), a high-affinity RNA analogue in which the ribose ring is chemically locked in a relatively rigid conformation by a 2ʹ-O,4ʹ-C methylene bridge. LNA-modified oligonucleotides possess high thermal stability when hybridized with their complementary mRNA targets as well as superior sensitivity and specificity in detecting corresponding miRNAs 205 . LNA-modified anti-miRNAs called antagomirs, which are antisense oligonucleotides that hybridize with target miRNAs, can inhibit specific miRNAs 28, 147, 206 . One such antagomir is being evaluated in clinical trials for the treatment of hepatitis C virus infection 205 . In the context of diabetes, administration of an LNA-modified inhibitor of miR-192 to mice with streptozotocin-induced diabetes inhibited both miR-192 and its downstream miRNAs (miR-216a, miR-217 and the miR-200 family), as well as p53 expression in the renal cortex, and reduced key parameters of DKD 28, 147, 148, 207 . Several studies have also reported efficacy of miR-21 inhibitors in mouse models of DKD [208] [209] [210] [211] , whereas another study showed that injection of 2ʹ-O-methyl antisense oligonucleotides, which target miR-29c, reduced rates of DKD in diabetic db/db mice 212 . The upstream mechanisms that control the expression and/or transcription of miRNAs could also be targeted to prevent or treat DKD. For example, the induction of miR-192 by TGFβ1 is mediated by SMAD2 and/or SMAD3 and acetylation of ETS1 and histones by the histone acetyltransferase p300 (which is activated by AKT) 30 , suggesting that miR-192 expression could be therapeutically targeted by inhibiting AKT or histone acetyltransferases to prevent DKD.
Despite the potential of miRNA-targeted therapies, it will be a challenge to avoid undesired off-target effects, especially in a heterogeneous organ such as the kidney. Stable, synthetic and biodegradable miRNA carriers, as well as optimal delivery methods, are being assessed to ensure efficiency without toxicity [213] [214] [215] [216] . Beyond miRNAs, Locked nucleic acid (lNA). A modified RNA nucleotide in which the ribose moiety is modified with an extra bridge connecting the 2′ oxygen and 4′ carbon. The bridge 'locks' the ribose in the 3′-endo conformation, which is often found in the A-form duplexes. lNA nucleotides are very stable and have high affinity for target DNA or RNA residues, to which they hybridize.
Antagomirs
Small synthetic RNAs that are designed to silence endogenous microRNAs. In addition to introducing locus-specific genetic changes, the CRISPR-Cas9 system can also be used to introduce locus-specific epigenetic changes, including the induction of DNA methylation (part a; by fusing Cas9 with DNA methyltransferase) or demethylation at specific sites (by fusing Cas9 with ten-eleven translocation (TET) proteins that convert 5-methylcytosine into 5-hydroxymethylcytosine) and the induction of histone modifications (part b), including histone acetylation (by fusing Cas9 with acetyltransferase), histone deacetylation (by fusing Cas9 with histone deacetylase), histone methylation (by fusing Cas9 with histone methyltransferase) and histone demethylation (by fusing Cas9 with histone demethylase). Such changes of epigenetic marks might facilitate the erasure of epigenetic memory and improve long-term outcomes for patients with diabetic kidney disease. gRNA , guide RNA.
a number of studies have demonstrated the value of targeting lncRNAs in DKD. Subcutaneous injection of an LNA-modified chimeric antisense oligonucleotide (GapmeR) that targets the DKD-associated lncRNA megacluster, lnc-MGC, led to accumulation of the GapmeR in the kidneys of diabetic mice, led to reduced expression of not only lnc-MGC but also key cluster miRNAs hosted within it and attenuated key features of early DKD 31 . A similar GapmeR that targets human lnc-MGC also reduced fibrotic gene expression in human mesangial cells cultured with high glucose or TGFβ to mimic diabetic conditions, suggesting translational potential of this agent for human DKD 31 . As described above, miR-379-EDEM3 and miR-494-ATF3 signalling can activate circuits that augment ER stress to induce persistent expression of lnc-MGC and miR-379 cluster miRNAs as a potential mechanism of metabolic memory; thus, GapmeR-mediated inhibition of lnc-MGC might confer additional benefits by erasing metabolic memory (Fig. 4) .
Epigenetic editing. Genome editing via CRISPR-Cas9 and other methods [217] [218] [219] [220] is a powerful approach to modify genetic and epigenetic changes. The CRISPR-Cas9 system is relatively easier and faster than other genome editing methods. It can be used to introduce site-specific mutations, large deletions and replacements, even in mammalian cells, and to create animal models harbouring such mutations [221] [222] [223] (Fig. 5) . By fusing Cas9 proteins with transcriptional activators or repressors, this system can also be used for the site-specific control of gene activation or repression 224, 225 . Similarly, fusion of Cas9 with DNA methyltransferases, TETs or histone-modifying enzymes enables locus-specific alteration of epigenetic marks, DNA methylation or histone acetylation or methylation, thus enabling erasure or reversal of epigenetic memory [226] [227] [228] [229] [230] [231] (FigS 3,6 ). In the future, such site-specific epigenetic modifications could be used to improve the efficacy of pharmacological treatments and overcome the broad off-target, nonspecific genomic effects of currently available epigenetic-modifying drugs.
Conclusions DKD pathogenesis is driven by complex interactions between metabolic and haemodynamic factors. Epigenetic mechanisms that might integrate these interactions include DNA and chromatin modifications, miRNAs and lncRNAs. Epigenetics therefore offers new insights into DKD that will complement GWAS data. Long-term persistence of epigenetic modifications and ncRNAs triggered by diabetic stimuli could be key mechanisms underlying metabolic memory. Several HMTs and corresponding histone PTMs, DNA methylation and multiple miRNAs and lncRNAs have been implicated in the expression of fibrotic and inflammatory genes associated with DKD. Approaches for controlling these molecules using small molecules or genetic interventions, including CRISPR-Cas9 editing, might lead to the development of new therapeutics for DKD and could potentially even erase metabolic memory. Ongoing efforts to evaluate epigenetic changes and ncRNA profiles in archived or freshly obtained biological samples, blood cells and renal tissues from clinical cohorts of patients with DKD and CKD will lead to the discovery of non-invasive biomarker signatures of renal function decline and DKD. Integrating epigenetic data sets with available genetic patient data using experimental and in silico methods is expected to accelerate the identification of new mediators of DKD progression.
As epigenetics mostly affects gene expression in a celltype-specific manner, challenges exist in the interpretation of epigenome data from heterogenous white blood cell samples and renal biopsy samples. Computational deconvolution approaches to correct for cell-type composition have partially overcome these hurdles 127, 232 , but additional reference data sets are needed. Research in the area of EWAS in DKD is highly active and expected to further escalate, as better computational deconvolution approaches, multi-omics reference data sets and human kidney single-cell sequencing data sets become available. This rapidly expanding field is aided by unprecedented technological and scientific advances in the fields of high-throughput sequencing, sophisticated bioinformatics and gene editing, as well as the wealth of publicly available data sets from the National Institutes of Health Roadmap Epigenetics Project, ENCODE and other international consortia. EWAS coupled with GWAS and other omics profiles, including data from enhancer and chromatin accessibility studies 83 , will help determine the functional relevance or causality of genetic variants, many of which occur in non-coding regulatory regions, including lncRNAs and enhancers.
Unlike genetics, epigenetic changes are mostly reversible, generating exciting opportunities for therapeutic intervention through the use of emerging approaches that enable locus-specific control of epigenetic marks. In addition, epigenetic biomarkers could support precision medicine approaches to optimally stratify patients for effective treatment (Fig. 7) . Thus, evaluation of epigenetic and epigenomic alterations is expected to yield new insights into the pathogenesis of DKD and metabolic memory that, in turn, can be translated into novel biomarkers and therapeutic modalities. Fig. 7 | Epigenetic and RNA profiling to support precision medicine. Epigenetic changes such as DNA methylation and histone modifications in patients represent potential biomarkers for particular renal diseases, including diabetic kidney disease (DKD). Locus-specific correction of such epigenetic changes using the CRISPR-Cas9 system could be a future avenue for patient-specific treatment. Circulating RNAs (including microRNAs and long non-coding RNAs) in biological fluids, such as blood and urine, or biopsy tissue are also potential diagnostic biomarkers for DKD. Synthetic chemical inhibitors of specific RNAs (for example, antisense oligonucleotides (for example, GapmeRs)) could also facilitate patient-specific treatment.
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